StockWatch
·
HomeLiveWeekly
Pharmaceuticals
USFDA2 Jul 2026, 03:05 pm

Onesource Pharma Facility Undergoes USFDA cGMP Inspection

AI Summary

Onesource Specialty Pharma Ltd announced that its Sterile Product Division facility in Bengaluru underwent a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA). The inspection, which took place from June 22 to June 30, 2026, concluded with one observation. The company stated it will provide a comprehensive response to the FDA within the stipulated timeframe and will keep the stock exchanges informed of further developments.

Key Highlights

  • USFDA conducted a routine cGMP inspection at Onesource Pharma's Sterile Product Division.
  • The inspection concluded with a single observation.
  • Company will submit a comprehensive response to the FDA.
  • Further developments will be communicated to stock exchanges.
View BSE Filing
ONESOURCE
Pharmaceuticals
Onesource Specialty Pharma Ltd

Price Impact

More from ONESOURCE

Insider Trading24 Jun, 6:20 pm

Onesource Specialty Pharma Closes Trading Window for Q1 FY27 Results

Management Change19 May, 10:45 am

Onesource Pharma: Prateek Gupta Resignation Acknowledged

Expansion16 May, 1:31 pm

Onesource Pharma Gets In-Principle Nod for Unit-II Expansion in Karnataka

More in USFDA

RUBICON1d ago, 5:40 pm

Rubicon Research Facility Undergoes US FDA Inspection

AJANTPHARM2d ago, 1:52 pm

Ajanta Pharma Paithan Facility Receives VAI Classification from USFDA

LUPIN3d ago, 10:00 pm

Lupin Receives US FDA EIR for Somerset Facility with VAI Classification